Peking University Cancer Hospital & Institute
Clinical trials sponsored by Peking University Cancer Hospital & Institute, explained in plain language.
-
New drug cocktail targets rare, aggressive melanoma
Disease control ENROLLING_BY_INVITATIONThis phase 1 trial tests two experimental drug combinations—AK104 or AK112 plus axitinib—in people with metastatic mucosal melanoma, a rare and hard-to-treat skin cancer. The study aims to find a safe dose and see whether the combinations shrink tumors. Participants receive the d…
Phase: PHASE1 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
AI biomarker may reveal who responds to esophageal cancer immunotherapy
Diagnosis OngoingThis trial tests whether a new AI-driven biomarker, called the Microbial-Sensory Coupling (MSC) index, can predict how well patients with esophageal squamous cell carcinoma respond to anti-PD-1 immunotherapy. The biomarker measures the spatial relationship between a specific bact…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC